Skip to main content
Premium Trial:

Request an Annual Quote

Diagnoplex Receives $1.4M from Investors to Support Colon Cancer Test

NEW YORK (GenomeWeb News) – Diagnoplex and Debiopharm Diagnostics, part of the Debiopharm Group, today announced that Diagnoplex has secured CHF1.3 million ($1.4 million) in financing.

Debiopharm led the round, while Neomed and Capital Romandie also participated in the financing.

Diagnoplex will use the funds to support its efforts to obtain CE marking for Colox, a non-invasive, blood-based test for the early detection of colorectal cancer. The Lausanne, Switzerland-based firm also hopes to prepare a comparative clinical trial for Colox.

Colox is a PCR-based gene signature test comprised of 29 biomarkers, according to Diagnoplex's website.

In a statement, Diagnoplex Founder and CEO Stavros Therianos said the funding will enable the firm to continue its development and progress in "establishing a collaboration for the commercialization of its diagnostic test."

Debiopharm also invested in Diagnoplex in early 2011. In its initial Series A financing round the company raised about $10.4 million.